Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Short term Debt (2022 - 2025)

Cue Biopharma's Short term Debt history spans 4 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Short term Debt fell 63.55% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, down 63.55%, while the annual FY2024 figure was $4.3 million, 9.34% up from the prior year.
  • Short term Debt for Q3 2025 was $1.5 million at Cue Biopharma, down from $2.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $4.3 million in Q4 2024 and bottomed at $1.0 million in Q3 2022.
  • The 4-year median for Short term Debt is $4.0 million (2023), against an average of $3.2 million.
  • The largest annual shift saw Short term Debt surged 300.0% in 2023 before it crashed 63.55% in 2025.
  • A 4-year view of Short term Debt shows it stood at $2.0 million in 2022, then surged by 101.88% to $4.0 million in 2023, then rose by 9.34% to $4.3 million in 2024, then plummeted by 66.35% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Short term Debt are $1.5 million (Q3 2025), $2.4 million (Q2 2025), and $3.4 million (Q1 2025).